Entro un mese, la Commissione Europea deciderà sulla revoca dell'autorizzazione del farmaco Tavneos, raccomandata dall'Ema per benefici incerti in malattie autoimmuni.
Home
Internazionale
Entro un mese, la Commissione Europea deciderà sulla revoca dell'autorizzazione del farmaco Tavneos, raccomandata dall'Ema per benefici incerti in malattie autoimmuni.
La sede provvisoria dell'Ema ad Amsterdam - Afp
29 giugno 2026 | 14.41
EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms
European Regulators Move to Revoke Avacopan Authorization
On second try, Acadia drug gets nod from European regulators
NEJM retracts pivotal data for Amgen's Tavneos
Lma, via libera Ue a estensione di indicazione per associazione orale
Lma, via libera Ue a estensione di indicazione per associazione orale - Il Quotidiano del Sud
Malattie rare – Dal CHMP parere positivo per trofinetide per il trattamento della sindrome di Rett
EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the…
As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators…
Trial data 'can no longer be relied upon' to demonstrate drug's efficacy, EMA committee says
An independent research firm is reviewing data on Amgen’s Tavneos as the company prepares for a hearing later this month with the…
The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma…
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth…
